Cue Biopharma Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Cue Biopharma Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- CUE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001645460
Board of directors
-
Aaron G.l. Fletcher · DirectorSince 2023
-
Daniel A. Camardo · DirectorSince 2026
-
Daniel R. Passeri · Director · CHIEF EXECUTIVE OFFICERSince 2023
-
Frank Morich · DirectorSince 2023
-
Frederick W. Driscoll · DirectorSince 2023
-
Jill Marie Broadfoot · DirectorSince 2025
-
Michael J. Fox · DirectorSince 2024
-
Pamela Garzone · DirectorSince 2023
-
Pasha Sarraf · DirectorSince 2025
-
Patrick Verheyen · DirectorSince 2023
-
Peter A. Kiener · DirectorSince 2023
-
Shao-Lee Lin · Director · Chief Executive OfficerSince 2026
-
Tamar D. Howson · DirectorSince 2023
-
Usman Azam · Director · CHIEF EXECUTIVE OFFICERSince 2025
-
Viola Mong Meehan · DirectorSince 2026
Chief executives
Shao-Lee Lin
· Chief Executive Officer
Since April 2026
Daniel R. Passeri
· CHIEF EXECUTIVE OFFICER
Until September 2025
· Former
Usman Azam
· CHIEF EXECUTIVE OFFICER
2025 – 2026
· Former
Board connections
7 of this board's directors also sit on 9 other boards.
- via Frederick W. Driscoll and Tamar D. Howson
- via Aaron G.l. Fletcher
- via Frederick W. Driscoll
- via Aaron G.l. Fletcher
- via Tamar D. Howson
- via Peter A. Kiener
- via Frank Morich
- via Shao-Lee Lin
- via Jill Marie Broadfoot
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $99,719
- 5 purchases by 1 insider
- Sold, last 12 months
- $2,041,514
- 11 sales by 3 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 13, 2026 | Sumita Ray Officer (Chief Legal Compliance Officer), Corporate Secretary | Option exercise | +18,196 | — | — |
| Aug 13, 2026 | Meluzio Michael Vincent Officer (VP, Prin. Accounting Officer) | Option exercise | +13,647 | — | — |
| Aug 13, 2026 | Sumita Ray Officer (Chief Legal Compliance Officer), Corporate Secretary | Open-market sale | −2,383 | $29.37 | $69,989 |
| Aug 13, 2026 | Meluzio Michael Vincent Officer (VP, Prin. Accounting Officer) | Open-market sale | −1,519 | $29.37 | $44,613 |
| Aug 13, 2026 | Sumita Ray Officer (Chief Legal Compliance Officer), Corporate Secretary | Open-market sale | −6,442 | $30.35 | $195,515 |
| Aug 13, 2026 | Meluzio Michael Vincent Officer (VP, Prin. Accounting Officer) | Open-market sale | −4,106 | $30.35 | $124,617 |
| Aug 13, 2026 | Shao-Lee Lin Director, Officer (Chief Executive Officer) | Open-market sale | −5,423 | $27.19 | $147,451 |
| Aug 13, 2026 | Sumita Ray Officer (Chief Legal Compliance Officer), Corporate Secretary | Open-market sale | −4 | $31.13 | $125 |
| Aug 13, 2026 | Meluzio Michael Vincent Officer (VP, Prin. Accounting Officer) | Open-market sale | −3 | $31.13 | $93 |
| Aug 13, 2026 | Shao-Lee Lin Director, Officer (Chief Executive Officer) | Open-market sale | −2,375 | $28.11 | $66,761 |
| Aug 13, 2026 | Shao-Lee Lin Director, Officer (Chief Executive Officer) | Open-market sale | −10,460 | $29.48 | $308,361 |
| Aug 12, 2026 | Shao-Lee Lin Director, Officer (Chief Executive Officer) | Option exercise | +109,179 | — | — |
| Aug 12, 2026 | Shao-Lee Lin Director, Officer (Chief Executive Officer) | Open-market sale | −34,225 | $26.99 | $923,733 |
| Aug 12, 2026 | Shao-Lee Lin Director, Officer (Chief Executive Officer) | Open-market sale | −5,775 | $27.75 | $160,256 |
| Jul 30, 2026 | Ahlers James M Officer (Chief Financial Officer) | Grant or award | +25,500 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.